BMRN Add to watchlist
$59.20 +0.00 (+0.00%)
Pre-Market: $58.64 0.56 (-0.95%)
Last updated: Jul 15, 2026 11:58
52-Week Range
$58.64
$49.26 $58.64 $66.28

Fundamentals Overview

BioMarin Pharmaceutical Inc. is in the middle of its 52-week range with premium valuation, trading relatively flat today.

Valuation premium

P/E 43.1 P/B 1.82 P/S 3.5

Intrinsic value (DCF)

-86.3% downside vs price

Profitability

Net margin 8.3%

Risk (Beta)

0.24 — lower vol

Earnings & growth

EPS $1.36 Rev -12.4% Profit +326.6% vs prior qtr

BullzEye Analysis

Our composite tilts Hold on technicals (e.g. RSI, ADX, trend), fundamentals, sentiment, sector and index context, and risk.

Composite Signal

Sell
Buy
Hold — 59% confidence Risk: Lower Volatility — Beta 0.24. Diversify and only invest what you can afford to lose.

Supporting (Buy):

Analyst grade: B

Pressures (Sell):

DCF 86.3% downside vs price · Sentiment weakening (2 downgrades)

Not financial advice. For education and research only; do your own research and consider a financial advisor before investing.

Key Stats

Market Cap
$11.33B
P/E (TTM)
43.13
EPS (TTM)
$1.36
Dividend Yield
N/A
52-Week Range
$49.26 - $66.28
Volume vs Avg
N/A
Beta
0.24

About

BioMarin Pharmaceutical Inc. specializes in creating and bringing to market treatments for individuals suffering from severe and often fatal rare disorders and other critical medical conditions. The company currently markets several key pharmaceutical products. Among these are Vimizim, an enzyme replacement therapy targeting mucopolysaccharidosis (MPS) IV type A, a specific lysosomal storage disorder, and Naglazyme, a recombinant form of N-acetylgalactosamine 4-sulfatase for individuals with MPS...
Sector: Healthcare
Headquarters: US
Employees: 3,221
IPO Date: Jul 1999
Beta: 0.24 (Less volatile than market)

Ratings & Grades at a Glance

Overall rating: B. Recent institutional grades: majority downgrades. Current institutional positions: Buy: 12, Hold: 1, Market Perform: 1, Neutral: 5, Outperform: 5, Overweight: 4, Sector Perform: 2.

Financial story & AI narrative

Open this tab to load the financial story.

Valuation & Ratios

Valuation, liquidity, and profitability metrics are consolidated here (including ratios that previously appeared in the Financials story). Trailing (TTM) vs forward-looking (e.g. DCF) is noted on each line where it matters.

DCF vs price: DCF estimate is $8.03; current price is $58.64. That’s a -86.3% gap. When the gap is large (e.g. >20%), that’s divergence; when they’re close, that’s convergence. Differences can reflect growth expectations, sector premiums, or conservative vs. optimistic assumptions. Use DCF as one input alongside technicals and sentiment.

Metric Value
Valuation
P/E (TTM) 43.13
DCF value (model) $8.03 (-86.3% vs price)
PEG (TTM) N/A
P/B (TTM) 1.82
P/S (TTM) 3.5
P/FCF (TTM) 14.78
Liquidity & enterprise
Current Ratio (TTM) 5.81
Quick Ratio (TTM) 4.2
Cash Ratio (TTM) 2.8
Profitability
ROE (TTM) N/A
ROA (TTM) N/A
Revenue growth (YoY) N/A
Net margin (TTM) 8.29%
Gross margin (TTM) 75.93%
Operating margin (TTM) 13.55%
Debt to equity (TTM) N/A

Latest News

News loads when you open this tab.

Price Target, Ratings & Grades

Analyst price targets, consensus, rating snapshot, and institutional grades for BMRN.

Analyst Sentiment at a Glance

B Sentiment Weakening
Buy 12Hold 1Market Perform 1Neutral 5Outperform 5Overweight 4Sector Perform 2
1 upgrade, 2 downgrades
Price Target Consensus
Current $58.64
Median $84.00
Consensus $87.40
Low consensus $50.00
High consensus $120.00

Stock Grades (Institutions)

Institution Action Previous Grade New Grade Date
RBC Capital maintain Sector Perform Sector Perform 2026-07-07
Canaccord Genuity maintain Buy Buy 2026-05-22
B of A Securities maintain Buy Buy 2026-05-19
HC Wainwright & Co. maintain Neutral Neutral 2026-05-18
Canaccord Genuity maintain Buy Buy 2026-05-07
Bernstein maintain Outperform Outperform 2026-05-05
RBC Capital maintain Sector Perform Sector Perform 2026-05-05
Evercore ISI Group maintain Outperform Outperform 2026-05-05
Morgan Stanley maintain Overweight Overweight 2026-05-05
HC Wainwright & Co. maintain Neutral Neutral 2026-05-05
B of A Securities maintain Buy Buy 2026-03-11
Barclays maintain Overweight Overweight 2026-03-04
Freedom Broker maintain Buy Buy 2026-03-02
HC Wainwright & Co. maintain Neutral Neutral 2026-03-02
Canaccord Genuity maintain Buy Buy 2026-02-26
HC Wainwright & Co. maintain Neutral Neutral 2026-02-25
Guggenheim maintain Buy Buy 2026-02-25
Bernstein maintain Outperform Outperform 2026-02-25
Oppenheimer maintain Outperform Outperform 2026-02-24
Wells Fargo maintain Overweight Overweight 2026-02-18
Piper Sandler maintain Overweight Overweight 2026-02-06
Canaccord Genuity upgrade Hold Buy 2026-01-20
Truist Securities maintain Buy Buy 2025-12-23
HC Wainwright & Co. maintain Neutral Neutral 2025-12-22
Leerink Partners downgrade Outperform Market Perform 2025-12-03
Stifel downgrade Buy Hold 2025-11-06
Bernstein maintain Outperform Outperform 2025-11-03
Freedom Broker maintain Buy Buy 2025-11-03
Stifel maintain Buy Buy 2025-10-28
Truist Securities maintain Buy Buy 2025-10-28